

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

C564 U.S. PTO  
09/766678  
01/23/01

Applicant: Axel ULLRICH et al.

Title: USE OF ORGANIC COMPOUNDS FOR THE  
INHIBITION OF FLK-1 MEDIATED  
VASCULOGENESIS AND ANGIOGENESIS

Prior Appl. No.: 08/193,829

Prior Appl. Filing Date: February 9, 1994

Examiner: Unassigned

Art Unit: Unassigned

**CONTINUING PATENT APPLICATION**  
**TRANSMITTAL LETTER**

Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is a:

[ X ] Continuation    [ ] Division    [ ] Continuation-In-Part (CIP)

of the above-identified copending prior application in which no patenting, abandonment, or termination of proceedings has occurred. Priority to the above-identified prior application is hereby claimed under 35 U.S.C. § 120 for this continuing application. The entire disclosure of the above-identified prior application is considered as being part of the disclosure of the accompanying continuing application and is hereby incorporated by reference therein.

[X] Amend the specification by inserting before the first line, the following sentence: --This application is a continuation of U.S. App. Ser. No. 08/965,598, filed November 6, 1997, and a continuation of U.S. App. Ser. No. 08/193,829, filed February 9, 1994, now U.S. Pat. No. 6,177,401, which is a continuation-in-part of U.S. App. Ser. No. 08/038,596, filed March 26, 1993, now abandoned, which is a continuation-in-part of U.S. App. Ser. No. 07/975,750, filed November 13, 1992, now abandoned.--

[ ] Applicant claims small entity status under 37 CFR 1.27.

Enclosed are:

[ X ] Specification, Claim(s), and Abstract (85 pages).

- Informal drawings (25 sheets, Figures 1-17).
- Unexecuted Declaration and Power of Attorney (2 pages).

The filing fee is calculated below:

	Claims As Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$710.00	\$710.00
Total Claims:	51	- 20	= 31	x \$18.00	= \$558.00
Independents:	16	- 3	= 13	x \$80.00	= \$1,040.00
If any Multiple Dependent Claim(s) present:				+ \$270.00	= \$270.00
Surcharge under 37 CFR 1.16(e) for late filing of Executed Declaration and late payment of filing fee				+ \$130.00	= \$130.00
				SUBTOTAL:	= \$2,708.00
<input type="checkbox"/> Small Entity Fees Apply (subtract ½ of above):					= \$0.00
				TOTAL FILING FEE:	= \$2,708.00

- A check in the amount of \$0.00 to cover the filing fee is enclosed.
- The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.
- The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Date 1/23/01

FOLEY & LARDNER  
 Washington Harbour  
 3000 K Street, N.W., Suite 500  
 Washington, D.C. 20007-5109  
 Telephone: (202) 672-5475  
 Facsimile: (202) 672-5399

Respectfully submitted,

By Beth A. Burrous

Beth A. Burrous  
 Attorney for Applicant  
 Registration No. 35,087

Flk-1 IS A RECEPTOR FOR VASCULAR  
ENDOTHELIAL GROWTH FACTOR

---

5

TABLE OF CONTENTS

	<u>Page</u>
1. <u>INTRODUCTION</u>	1
10 2. <u>BACKGROUND OF THE INVENTION</u>	1
3. <u>SUMMARY OF THE INVENTION</u>	3
4. <u>BRIEF DESCRIPTION OF THE FIGURES</u>	4
15	
5. <u>DETAILED DESCRIPTION OF THE INVENTION</u>	9
20 5.1. <u>THE Flk-1 CODING SEQUENCE</u>	12
5.2. EXPRESSION OF Flk-1 RECEPTOR AND GENERATION	
25 5.2.1. <u>EXPRESSION SYSTEMS</u>	17
5.2.2. IDENTIFICATION OF TRANSFECTANTS OR TRANSFORMANTS THAT EXPRESS THE Flk-1	24
25 5.3. USES OF THE Flk-1 RECEPTOR AND ENGINEERED CELL LINES	26
30 5.3.1. SCREENING OF PEPTIDE LIBRARY WITH Flk-1 PROTEIN OR ENGINEERED CELL LINES	28
30 5.3.2. SCREENING OF ORGANIC COMPOUNDS WITH Flk-1 PROTEIN OR ENGINEERED CELL LINES	30
35 5.3.3. <u>ANTIBODY PRODUCTION AND</u> <u>SCREENING</u>	34

	<u>Page</u>
5.4. <u>USES OF Flk-1 CODING SEQUENCE</u> . . . . .	36
5.4.1. <u>USE OF Flk-1 CODING SEQUENCE</u> <u>IN DIAGNOSTICS AND THERAPEUTICS</u> . . . . .	37
5.4.2. <u>USE OF DOMINANT</u> <u>NEGATIVE</u> <u>Flk-1 MUTANTS IN GENE THERAPY</u> . . . . .	40
10     5.5. <u>USE OF Flk-1 RECEPTOR OR LIGANDS</u> . . . . .	43
. . . . .	48
15     6. EXAMPLE: <u>CLONING AND EXPRESSION PATTERNS</u> <u>OF Flk-1, A HIGH AFFINITY RECEPTOR FOR VEGF</u> . . . . .	50
20       6.1. <u>MATERIALS AND METHODS</u> . . . . .	51
25        6.1.1. <u>cDNA CLONING OF Flk-1</u> . . . . .	51
6.1.2. <u>MOUSE EMBRYOS</u> . . . . .	51
6.1.3. <u>PREPARATION OF PROBES</u> . . . . .	52
6.1.4. <u>RNA EXTRACTION AND</u> <u>NORTHERN ANALYSIS</u> . . . . .	52
6.1.5. <u>IN SITU HYBRIDIZATION</u> . . . . .	53
6.1.6. <u>PREPARATION OF ANTISERA</u> . . . . .	53
6.1.7. <u>TRANSIENT EXPRESSION</u> <u>OF Flk-1 IN COS-1 CELLS</u> . . . . .	54
6.1.8. <u>RADIOIODINATION OF VEGF</u> . . . . .	55
6.1.9. <u>CROSSLINKING OF VEGF TO Flk-1</u> . . . . .	55
6.1.10. <u>VEGF BINDING</u> . . . . .	56
30        6.1.11. <u>RETROVIRAL VECTORS ENCODING</u> <u>TRANSDOMINANT-NEGATIVE MUTANTS</u> <u>OF Flk-1</u> . . . . .	57
35        6.1.12. <u>THE CAPABILITY OF FLK-1 TM TO</u> <u>FORM</u> <u>SIGNALLING-INCOMPETENT HETERODIMERS</u> . . . . .	57
6.1.13. <u>INTRACEREBRAL GRAFTING</u>	

	<u>Page</u>
	61
	OF GLIOMA CELLS . . . . .
5	6.1.14. ASSAY FOR AND IDENTIFICATION OF ORGANIC COMPOUNDS THAT MODULATE <u>FLK-1 MEDIATED SIGNAL TRANSDUCTION</u> . . . . .
	63
	6.1.15. SYNTHESIS OF A 3-PHENYL-1, <u>4-DIAZA-ANTHRACENE</u> . . . . .
	64
	6.2. <u>RESULTS</u> . . . . .
	64
10	6.2.1. <u>ISOLATION OF Flk-1</u> . . . . .
	64
	6.2.2 EXPRESSION OF Flk-1 mRNA <u>DURING EMBRYONIC DEVELOPMENT</u> . . . . .
	65
	6.2.3. EXPRESSION OF Flk-1 <u>DURING ORGAN ANGIOGENESIS</u> . . . . .
	67
15	6.2.4. Flk-1 EXPRESSION IN <u>ENDOTHELIAL CELL PROGENITORS</u> . . . . .
	68
	6.2.5. Flk-1 IS A HIGH AFFINITY <u>RECEPTOR FOR VEGF</u> . . . . .
	68
	6.2.6. INHIBITION OF TUMOR GROWTH BY TRANSDOMINANT-NEGATIVE <u>INHIBITION OF Flk-1</u> . . . . .
20	70
	6.2.7. IDENTIFICATION OF AN ORGANIC COMPOUND THAT INHIBITS FLK-1 <u>RECEPTOR PHOSPHORYLATION</u> . . . . .
	72
25	
30	
35	